Center for Scientific Review; Notice of Closed Meeting, 65698 [2012-26602]
Download as PDF
<![CDATA[
65698
Federal Register / Vol. 77, No. 210 / Tuesday, October 30, 2012 / Notices
Dated: October 24, 2012.
Mary K. Wakefield,
Administrator.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
wreier-aviles on DSK7SPTVN1PROD with NOTICES
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Dating
Violence and Marketing.
Date: November 13, 2012.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Anna L Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 24, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–26602 Filed 10–29–12; 8:45 am]
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
[FR Doc. 2012–26565 Filed 10–29–12; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prospective Grant of Exclusive
Evaluation Option License: Pre-clinical
Evaluation of Human Therapeutics
Utilizing Ubiquitin Based Fusion
Proteins With Apoptosis Modifying
Proteins Such as BCL–XL
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National
Institute of Diabetes and Digestive and
Kidney Diseases Special Emphasis
Panel, Ancillary Studies to the ISC
Consortium.
Date: November 29, 2012.
Time: 3:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Two Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Maria E. DavilaBloom, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National
Institutes of Health, Room 758, 6707
Democracy Boulevard, Bethesda, MD
20892–5452, (301) 594–7637, davilabloomm@extra.niddk.nih.gov.
Dated: October 23, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
evaluation option license to practice the
inventions covered under the scope of
United States Patent No. 6,737,511
issued May 18, 2004 entitled ‘‘Receptormediated Uptake of an Extracellular
BCL-xL Fusion Protein Inhibits
Apoptosis’’ (HHS Ref. No. E–073–1999/
0–US–02; Inventors Richard Youle et
al.) and International Patent Application
No. PCT/US2012/032762 filed April 9,
2012 entitled ‘‘Ubiquitin Fusions for
Improving the Efficacy of Cytosolic
Acting Targeted Toxins’’ (HHS Ref. No.
E–150–2011/0–PCT–02; Inventors
Christopher Bachran et al.) to
Medicenna Therapeutics,
(‘‘MEDICENNA’’) a Canada based
company. The patent rights in this
invention have been assigned to the
government of the United States of
America.
The prospective exclusive evaluation
option license territory may be
worldwide and the field of use may be
limited to the pre-clinical evaluation of
lead therapeutic candidates for the
development of human therapeutics
within the field of cancer and
neurological diseases. Upon expiration
or termination of the exclusive
evaluation option license, MEDICENNA
will have the right to execute an
exclusive patent commercialization
license which will supersede and
replace the exclusive evaluation option
license with no broader territory than
granted in the exclusive evaluation
option license and the field of use will
be commensurate with the commercial
development plan at the time of
conversion.
[FR Doc. 2012–26603 Filed 10–29–12; 8:45 am]
DATES:
(Catalogue of Federal Domestic
Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic
Research; 93.848, Digestive Diseases and
Nutrition Research; 93.849, Kidney
Diseases, Urology and Hematology
Research, National Institutes of Health,
HHS)
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
VerDate Mar<15>2010
13:17 Oct 29, 2012
Jkt 229001
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
SUMMARY:
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
November 14, 2012 will be considered.
E:\FR\FM\30OCN1.SGM
30OCN1
]]>Agencies
[Federal Register Volume 77, Number 210 (Tuesday, October 30, 2012)]
[Notices]
[Page 65698]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-26602]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Dating Violence and Marketing.
Date: November 13, 2012.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Anna L Riley, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892, 301-435-
2889, rileyann@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: October 24, 2012.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-26602 Filed 10-29-12; 8:45 am]
BILLING CODE 4140-01-P
